Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
350 Ppm Biotech GmbH is navigating 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This workload is distributed across 1 distinct examiner and 1 distinct art unit, reflecting a narrow scope of current prosecution activity. The concentration of the entire pending portfolio into 1 distinct art unit suggests that the company's current patenting efforts are focused on a specific biotechnological application.
MONSHIPOURI, MARYAM serves as the busiest examiner, currently overseeing 1 busiest examiner pending action. Since this 1 busiest examiner pending action represents the total volume of 1 pending office action for the company, the relationship with this specific examiner is critical. The lack of multiple examiners means the company cannot leverage different examiner perspectives to inform its broader strategy.
The presence of 1 pending office action under the guidance of 1 distinct examiner simplifies the management of the portfolio. Because MONSHIPOURI, MARYAM is the only examiner involved, the prosecution path is entirely dependent on this single interaction. This 1 to 1 ratio of actions to examiners highlights a singular point of focus for the company's legal representatives in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONSHIPOURI, MARYAM | 1 | 79.2% | +37.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18688431 | CARBON DIOXIDE-CONSUMING EXPRESSION SYSTEM | MONSHIPOURI, MARYAM | 4d overdue |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18688431 | CARBON DIOXIDE-CONSUMING EXPRESSION SYSTEM | MONSHIPOURI, MARYAM | 1651 | §112 | Final Rejection | 4d overdue | Pending | Mar 01, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial350 Ppm Biotech GmbH has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Maryam Monshipouri has the most, with 1 of 350 Ppm Biotech GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.